A detailed history of Met Life Investment Management, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 21,093 shares of NUVL stock, worth $1.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21,093
Previous 19,737 6.87%
Holding current value
$1.42 Million
Previous $2.02 Million 18.23%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$77.87 - $104.93 $105,591 - $142,285
1,356 Added 6.87%
21,093 $1.65 Million
Q3 2024

Nov 13, 2024

BUY
$67.44 - $112.17 $83,018 - $138,081
1,231 Added 6.65%
19,737 $2.02 Million
Q2 2024

Aug 13, 2024

BUY
$62.76 - $81.61 $281,666 - $366,265
4,488 Added 32.02%
18,506 $1.4 Million
Q1 2024

May 14, 2024

BUY
$72.35 - $88.99 $1.01 Million - $1.25 Million
14,018 New
14,018 $1.05 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $52,431 - $99,226
1,236 Added 9.67%
14,018 $1.03 Million
Q3 2023

May 09, 2024

BUY
$39.12 - $49.85 $73,545 - $93,718
1,880 Added 17.24%
12,782 $587,000
Q2 2023

Apr 29, 2024

BUY
$23.58 - $44.68 $301,399 - $571,099
12,782 New
12,782 $539,000
Q2 2023

Aug 10, 2023

BUY
$23.58 - $44.68 $44,330 - $83,998
1,880 Added 17.24%
12,782 $539,000
Q1 2023

May 09, 2024

BUY
$25.42 - $33.52 $277,128 - $365,435
10,902 New
10,902 $284 Million
Q4 2022

May 10, 2024

SELL
$18.46 - $36.37 $37,972 - $74,813
-2,057 Reduced 15.87%
10,902 $324,000
Q4 2022

Mar 22, 2023

SELL
$18.46 - $36.37 $37,972 - $74,813
-2,057 Reduced 15.87%
10,902 $324,000
Q4 2022

Feb 15, 2023

SELL
$18.46 - $36.37 $37,972 - $74,813
-2,057 Reduced 15.87%
10,902 $324,000
Q3 2022

Jun 14, 2023

BUY
$13.55 - $19.92 $27,872 - $40,975
2,057 Added 18.87%
12,959 $251,000
Q2 2022

Jun 20, 2023

BUY
$7.4 - $15.07 $15,221 - $30,998
2,057 Added 18.87%
12,959 $175,000
Q1 2022

May 10, 2024

BUY
$11.65 - $19.57 $150,972 - $253,607
12,959 New
12,959 $180,000
Q1 2022

Jun 20, 2023

BUY
$11.65 - $19.57 $23,964 - $40,255
2,057 Added 18.87%
12,959 $180,000
Q1 2022

Mar 22, 2023

BUY
$11.65 - $19.57 $100,073 - $168,106
8,590 Added 196.61%
12,959 $180,000
Q1 2022

May 12, 2022

BUY
$11.65 - $19.57 $100,073 - $168,106
8,590 Added 196.61%
12,959 $180,000
Q4 2021

Jun 21, 2023

SELL
$18.01 - $30.1 $117,659 - $196,643
-6,533 Reduced 59.92%
4,369 $83,000
Q3 2021

May 17, 2024

SELL
$18.25 - $38.35 $176,094 - $370,039
-9,649 Reduced 68.83%
4,369 $98,000
Q3 2021

Jun 21, 2023

SELL
$18.25 - $38.35 $119,227 - $250,540
-6,533 Reduced 59.92%
4,369 $98,000
Q3 2021

Mar 22, 2023

SELL
$18.25 - $38.35 $119,227 - $250,540
-6,533 Reduced 59.92%
4,369 $98,000
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $79,734 - $167,551
4,369 New
4,369 $99,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $2.9B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.